BCMA×CD3 bispecific T-cell–redirecting antibody that brings T cells into proximity with BCMA-positive myeloma cells.
Bispecific antibody that binds CD3 on T cells and BCMA (TNFRSF17) on myeloma cells, bringing T cells into close proximity to BCMA-positive plasma cells to form an immune synapse and trigger CTL activation and perforin/granzyme-mediated lysis of the tumor cells.
YES
DIRECT
Teclistamab links CD3+ T cells to BCMA+ cells, triggering CTL activation and immune-synapse–mediated perforin/granzyme cytolysis of the BCMA-expressing cells.
BCMA×CD3 bispecific T-cell–redirecting antibody that brings T cells into proximity with BCMA-positive myeloma cells.
Bispecific antibody that binds CD3 on T cells and BCMA (TNFRSF17) on myeloma cells, bringing T cells into close proximity to BCMA-positive plasma cells to form an immune synapse and trigger CTL activation and perforin/granzyme-mediated lysis of the tumor cells.
NO
INDIRECT
Teclistamab binds CD3 on T cells to activate them and redirect cytotoxicity toward BCMA-positive myeloma cells; killing occurs via perforin/granzyme-mediated lysis of BCMA+ targets, not CD3+ cells.
Also known as PRO1107, a PTK7-targeted monoclonal antibody–drug conjugate (ADC) that binds PTK7 on tumor cells, is internalized, and releases a cytotoxic payload to induce tumor cell death.
PTK7-targeted monoclonal antibody-drug conjugate that binds PTK7 on tumor cells, is internalized, and releases an intracellular cytotoxic payload via linker cleavage, leading to tumor cell death.
YES
DIRECT
An anti-PTK7 antibody-drug conjugate binds PTK7 on the cell, is internalized, and upon linker cleavage releases an intracellular cytotoxic payload that kills the PTK7-expressing cell.
Anti‑HER2 monoclonal antibody that inhibits HER2 signaling and mediates antibody‑dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody that binds HER2 (ERBB2), blocks receptor dimerization and downstream signaling (e.g., PI3K/AKT, MAPK), promotes receptor internalization/degradation, and engages immune effector cells via Fc to mediate ADCC against HER2‑overexpressing tumor cells.
YES
DIRECT
Fc-mediated ADCC via FcγR-expressing immune cells (e.g., NK cells) against HER2+ cells; may also contribute via CDC and apoptosis from HER2 signaling blockade.
Humanized IgG1 anti-HER2 monoclonal antibody that binds HER2, inhibits downstream signaling (PI3K/AKT, MAPK), reduces receptor dimerization, and mediates ADCC.
Humanized IgG1 monoclonal antibody targeting HER2; binds HER2 on tumor cells, inhibits receptor dimerization and downstream PI3K/AKT and MAPK signaling, and engages Fcγ receptors to trigger antibody-dependent cellular cytotoxicity (ADCC).
YES
DIRECT
Trastuzumab binds HER2 on target cells and its Fc engages Fcγ receptors on NK cells and other effectors to trigger antibody‑dependent cellular cytotoxicity (ADCC); may also activate complement; additionally inhibits HER2 signaling (primarily cytostatic).